The mhGAP guideline is a valuable resource for countries looking to improve their ability to address the increasing challenges of mental, neurological, and substance use (MNS) conditions. With 30 updated and 18 new recommendations, along with 90 existing recommendations, this latest edition is the third iteration of the guideline and reflects years of investment in the mhGAP programme.

The need for improved capacity to address MNS conditions is growing, and the mhGAP guideline aims to assist countries in meeting this challenge. The revised recommendations are designed to ensure that mhGAP provides non-specialist health workers in low and middle-income countries with high-quality, timely, transparent, and evidence-based guidance to effectively treat and care for individuals with MNS conditions.

With a focus on narrowing the treatment gap, the latest edition of the guideline includes 30 updated recommendations and 18 new recommendations, in addition to the 90 pre-existing recommendations. This represents the third iteration of the guideline and is the result of significant investment in the mhGAP programme over the past 15 years. By providing up-to-date guidance and resources, mhGAP can help bridge this gap and ensure that individuals with MNS conditions receive the care they need.